Press Releases Detail:
AVITAR Launches ORALscreen OSR
Companion to ORALscreen Permits Automated Analysis, Data Storage and Communication - Expands Market Opportunity
June 25, 2002
CANTON, Mass., June 25 /PRNewswire-FirstCall/ -- Avitar, Inc. (Amex: - ) today announced that it has launched ORALscreen OSR(TM), an instrument which automates the analysis of the ORALscreen rapid drugs-of-abuse test. In addition, test results can be stored and transmitted to remote locations. The Company plans to begin filling orders by the end of June.
"The ORALscreen OSR is the result of our continuing efforts to satisfy our customer needs by providing state-of-the-art products," said Peter P. Phildius. "The automated interpretation, data management and transmission capabilities of this instrument will allow corporations that require electronic data management to benefit from the significant advantages of our ORALscreen oral fluid-based rapid drugs-of-abuse test. The initial response has been very encouraging, and we will begin to fill our backlog of orders immediately. ORALscreen OSR will help us maintain our leadership role in the oral fluid-based, rapid drugs-of-abuse testing market."
The ORALscreen OSR is a hand-held instrument capable of reading and interpreting the results of Avitar's ORALscreen drugs-of-abuse test within 60 seconds. In addition to providing quick and accurate results, the instrument can also provide capabilities to the customer for recording, reporting and managing information utilizing various communication channels and storage medium.
Avitar, Inc. develops, manufactures and markets innovative and proprietary products in the oral fluid diagnostic market, and the disease and clinical testing market. Oral fluid diagnostics includes the estimated $1.5 billion drugs-of-abuse testing market, which encompasses the corporate workplace and criminal justice markets. Avitar's products include ORALscreen(TM), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, and HAIRscreen(TM), a laboratory-based hair test for detecting long-term drug abuse. In the estimated $25 billion In-Vitro diagnostics market, Avitar is developing diagnostic strategies for disease and clinical testing. Some examples include influenza, diabetes and pregnancy. For more information, see Avitar's website at avitarinc.com.
Safe Harbor Statement. This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
Lippert/Heilshorn and Associates